“April 2017 : Intensification of the Company’s international development with the appointment of a new CEO : Mrs Nawal Ouzren”
“Sensorion aims to become a major player in the development of inner ear disease treatments of and thus fulfill unmet medical needs”
"Our mission is to develop innovative and targeted treatments for inner ear diseases with vertigo, tinnitus, hearing loss"
" Sensorion, has received “French Tech Pass” certification, and thus joins an exclusive circle of innovative French technology companies with substantial development potential"


Sensorion develops innovative therapies dedicated to the treatment of vestibular and cochlear pathologies. Our scientists are focused on :

  • Relieving acute symptoms such as vertigo and tinnitus,
  • Reducing impairments (loss of balance, hearing loss ...) related to permanent damage of the inner ear,
  • Restore, to the extent possible, the functions already impacted.

Beginning in 2015, Sensorion launched the first clinical trial (phase 1b) with SENS-111, an innovative treatment against acute vertigo. SENS-111 will initially be tested on healthy volunteers to determine pharmacokinetics and tolerability.

Two other programs are also in the final stages of preclinical testing and Sensorion continues further development through international collaborations with academic research teams and Pharma companies.